Vanderbilt Heart and Vascular Institute Archives
Sep. 15, 2021—Vanderbilt has reached a new milestone in implanting CardioMEMS remote cardiac monitoring devices.
Sep. 9, 2021—Vanderbilt Heart and Vascular Institute continues to offer the latest in therapies to treat atrial fibrillation (AF or AFib), the most common cardiac arrhythmia.
Sep. 2, 2021—Brandon Cochran, a 39-year-old real estate agent in Louisville, Kentucky, was at home with his family in October 2020 when he went into cardiac arrest. His implanted defibrillator shocked him back to life, and he was hospitalized for seven months.
Aug. 12, 2021—The Structural Heart and Valve Center at Vanderbilt Heart and Vascular Institute (VHVI) has recently completed multiple groundbreaking transcatheter clinical trial procedures treating severe regurgitation of the mitral and tricuspid valves, a continuation of a decade of research that is revolutionizing the treatment of these conditions.
Jun. 9, 2021—The Anticoagulation Clinic at Vanderbilt Heart and Vascular Institute (VHVI) has been designated an Anticoagulation Center of Excellence by the Anticoagulation Forum, one of only three in Tennessee.
Mar. 10, 2021—In suburban Murfreesboro, just a short drive off Interstate 24, is one of the most diverse practices and clinics in Vanderbilt Health.
Jan. 21, 2021—The Adult Congenital Heart Association (ACHA) has awarded the Vanderbilt Adult Congenital Heart Program status as an Adult Congenital Heart Disease (ACHD) Accredited Comprehensive Care Center — the first in Tennessee.
Jan. 7, 2021—Jane Freedman, MD, will join Vanderbilt University Medical Center as director of the Division of Cardiovascular Medicine and the physician-in-chief of the Vanderbilt Heart and Vascular Institute, effective Aug. 1.
Dec. 10, 2020—Two Vanderbilt Heart and Vascular Institute researchers are receiving awards from the American Heart Association.
Oct. 22, 2020—A minimally invasive procedure that combines ligation of the left atrial appendage (LAA) with hybrid epicardial-endocardial ablation is a feasible, safe and effective method of treating patients with longstanding atrial fibrillation (AF or AFib), according to a new Vanderbilt-led study.